-

Coventry Study Finds Lapetus Life Expectancies Are Shorter Than Competitors in 85% of Cases Reviewed

FORT WASHINGTON, Pa.--(BUSINESS WIRE)--Coventry today released the results of an internal review that found life expectancy estimates issued by Lapetus Solutions, Inc. are consistently and materially shorter than those issued by other life expectancy providers, potentially leading to the overvaluation of life insurance policies and investor losses. The results cast doubt on the accuracy of asset valuations based primarily on Lapetus life expectancies.

After reviewing thousands of Lapetus life expectancy estimates, Coventry found that they are shorter than other leading life expectancy providers 85% of the time when comparing the same individuals. This suggests that their use of a general population base mortality table (rather than an insured population base mortality table) for life settlement underwriting contributes to their significantly shorter life expectancy estimates. A general population table is typically not used for these valuations because insured individuals over 65—those underwritten in any life settlement transaction—have average life expectancies more than three years longer than the general population. Study details are available at: coventry.com/research.

Coventry believes the impact on investors could be substantial and highly consequential. The insured’s life expectancy is the single most important factor when determining the value of a life settlement.

When inaccurately short life expectancies cause such assets to be overvalued, it sets the stage for liquidity issues and potential investor losses. Indeed, there are numerous examples of significant life settlement losses arising from faulty life expectancies.

“It is essential for the integrity of the market and the welfare of investors that life expectancy providers use best practices and issue reliable estimates,” said Alan Buerger, Coventry’s Executive Chairman. “As a licensed life settlement provider, we are committed to upholding industry regulations and guidelines to maintain credibility and protect stakeholders.”

Coventry is the leader and creator of the secondary market for life insurance. For more than 25 years, we have been driving the industry forward and expanding opportunities for life insurance policyowners. Coventry’s deep experience combined with a fierce commitment to consumer rights makes Coventry the clear market leader, a position we use to raise industry standards and expand consumer choice. To date, we have delivered more than $5.4 billion to policyowners who no longer need their policies. To learn more about Coventry, please visit Coventry.com.

For further information or to schedule an interview, please contact Brian Glicklich at Digital Strategy Ltd., Brian@DigitalStrategyLtd.com or 818-867-9096

Contacts

Brian Glicklich
Digital Strategy Ltd.
Brian@DigitalStrategyLtd.com
818-867-9096

Coventry


Release Summary
Coventry Study Finds Lapetus Life Expectancies Are Shorter Than Competitors in 85% of Cases Reviewed
Release Versions

Contacts

Brian Glicklich
Digital Strategy Ltd.
Brian@DigitalStrategyLtd.com
818-867-9096

More News From Coventry

Coventry: Flaws of Lapetus Life Expectancy Estimates Evaluated in New Study

FORT WASHINGTON, Pa.--(BUSINESS WIRE)--Coventry today announced the availability of a new study conducted by Professors Daniel Bauer and Nan Zhu, which revealed that life expectancy estimates produced by Lapetus Solutions, Inc. significantly understate the actual life expectancies of insureds. This serious flaw raises concerns about the accuracy of Lapetus’s mortality predictions, which could have significant repercussions for investors in life settlements. The study evaluates the accuracy of L...

Coventry Releases Peer Review of Lapetus Life Expectancy Study

FORT WASHINGTON, Pa.--(BUSINESS WIRE)--Coventry today released an independent, academic peer review confirming the results of an internal analysis of life expectancy estimates issued by leading life expectancy providers. That analysis found that estimates issued by Lapetus Solutions, Inc. are consistently the shortest by a wide margin—meaning that valuations based on Lapetus life expectancies could lead to significantly inflated asset values and investor losses. The review of the Coventry findi...
Back to Newsroom